Cutler Group LP Neurocrine Biosciences Inc Transaction History

Cutler Group LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$75.79 - $100.07 $30,316 - $40,028	-400 Reduced 76.34%	124 $12,000
Q1 2022 Apr 14, 2022	BUY	$72.45 - $94.81 $23,039 - $30,149	318 Added 154.37%	524 $49,000
Q4 2021 Jan 18, 2022	BUY	$79.65 - $106.22 $12,982 - $17,313	163 Added 379.07%	206 $17,000
Q3 2021 Oct 26, 2021	SELL	$86.18 - $99.03 $306,542 - $352,249	-3,557 Reduced 98.81%	43 $4,000
Q2 2021 Jul 19, 2021	BUY	$89.43 - $102.27 $268,290 - $306,810	3,000 Added 500.0%	3,600 $350,000
Q1 2021 Apr 26, 2021	SELL	$87.57 - $119.4 $123,210 - $167,995	-1,407 Reduced 70.1%	600 $58,000
Q4 2020 Jan 21, 2021	BUY	$86.91 - $108.33 $65,790 - $82,005	757 Added 60.56%	2,007 $192,000
Q3 2020 Oct 27, 2020	BUY	$96.16 - $135.15 $81,736 - $114,877	850 Added 212.5%	1,250 $120,000
Q2 2020 Jul 22, 2020	SELL	$85.09 - $130.36 $297,815 - $456,260	-3,500 Reduced 89.74%	400 $48,000
Q3 2019 Oct 28, 2019	SELL	$83.82 - $101.5 $377,189 - $456,750	-4,500 Reduced 53.57%	3,900 $351,000
Q2 2019 Aug 09, 2019	BUY	$72.24 - $91.27 $260,569 - $329,210	3,607 Added 75.26%	8,400 $709,000
Q1 2019 May 10, 2019	SELL	$69.31 - $91.53 $135,154 - $178,483	-1,950 Reduced 28.92%	4,793 $422,000
Q4 2018 Feb 05, 2019	SELL	$68.32 - $124.36 $1.23 Million - $2.25 Million	-18,058 Reduced 72.81%	6,743 $481,000
Q4 2017 Jan 17, 2018	SELL	$58.53 - $77.59 $1.27 Million - $1.68 Million	-21,670 Reduced 46.63%	24,801 $1.92 Million
Q3 2017 Oct 17, 2017	BUY	$47.97 - $61.28 $2.23 Million - $2.85 Million	46,471	46,471 $2.85 Million

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.